South Korean (KOSPI) Pharma Industry Analysis
UpdatedFeb 05, 2023
DataAggregated Company Financials
Companies100
- 7D1.9%
- 3M8.8%
- 1Y-13.9%
- YTD1.8%
Over the last 7 days, the Pharma industry has risen 2.5%, driven by gains from Caregen of 37%. During this same period, the SK Biopharmaceuticals underperformed, falling 5.1%. In contrast, the industry has lost 14% in the last 12 months. Looking forward, earnings are forecast to grow by 32% annually.
Industry Valuation and Performance
Has the South Korean Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 05 Feb 2023 | ₩46.4t | ₩27.7t | ₩743.5b | 20.4x | 62.4x | 1.7x |
| Tue, 03 Jan 2023 | ₩45.6t | ₩28.0t | ₩770.2b | 20x | 59.2x | 1.6x |
| Thu, 01 Dec 2022 | ₩45.0t | ₩28.0t | ₩767.8b | 19x | 58.5x | 1.6x |
| Sat, 29 Oct 2022 | ₩42.2t | ₩27.2t | ₩694.8b | 20.5x | 60.8x | 1.5x |
| Mon, 26 Sep 2022 | ₩42.7t | ₩27.5t | ₩720.9b | 20.1x | 59.3x | 1.6x |
| Wed, 24 Aug 2022 | ₩48.5t | ₩26.8t | ₩469.4b | 21.5x | 103.4x | 1.8x |
| Fri, 22 Jul 2022 | ₩51.3t | ₩26.7t | ₩475.9b | 22.8x | 107.9x | 1.9x |
| Sun, 19 Jun 2022 | ₩47.2t | ₩26.7t | ₩475.9b | 21.2x | 99.2x | 1.8x |
| Tue, 17 May 2022 | ₩52.7t | ₩26.1t | ₩670.0b | 25.3x | 78.6x | 2x |
| Thu, 14 Apr 2022 | ₩55.8t | ₩26.1t | ₩674.3b | 26.4x | 82.7x | 2.1x |
| Sat, 12 Mar 2022 | ₩55.9t | ₩25.0t | ₩927.2b | 23.7x | 60.3x | 2.2x |
| Mon, 07 Feb 2022 | ₩53.0t | ₩25.0t | ₩934.5b | 21.8x | 56.7x | 2.1x |
| Wed, 05 Jan 2022 | ₩61.0t | ₩25.0t | ₩934.5b | 24.6x | 65.3x | 2.4x |
| Fri, 03 Dec 2021 | ₩58.0t | ₩25.0t | ₩936.5b | 24.8x | 61.9x | 2.3x |
| Sun, 31 Oct 2021 | ₩61.2t | ₩24.7t | ₩876.1b | 23.9x | 69.8x | 2.5x |
| Tue, 28 Sep 2021 | ₩68.7t | ₩24.9t | ₩890.6b | 28x | 77.2x | 2.8x |
| Thu, 26 Aug 2021 | ₩71.9t | ₩26.0t | ₩960.3b | 39.2x | 74.8x | 2.8x |
| Fri, 02 Jul 2021 | ₩73.4t | ₩25.3t | ₩928.3b | 40.5x | 79.1x | 2.9x |
| Mon, 05 Apr 2021 | ₩66.4t | ₩24.9t | ₩915.5b | 33x | 72.5x | 2.7x |
| Thu, 07 Jan 2021 | ₩87.9t | ₩24.7t | ₩894.2b | 37.3x | 98.3x | 3.6x |
| Wed, 30 Sep 2020 | ₩73.8t | ₩24.4t | ₩499.4b | 32.2x | 147.7x | 3x |
| Sat, 04 Jul 2020 | ₩49.1t | ₩23.9t | ₩745.7b | 24.5x | 65.8x | 2.1x |
| Tue, 07 Apr 2020 | ₩38.3t | ₩23.6t | ₩732.3b | 19.6x | 52.3x | 1.6x |
Price to Earnings Ratio
56.8x
Current Industry PE
- Investors are pessimistic on the South Korean Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 62.5x which is lower than its 3-year average PE of 82.9x.
- The 3-year average PS ratio of 2.3x is higher than the industry's current PS ratio of 1.7x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 6.2% per year over the last three years.
- Revenues for these companies have grown 6.3% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare industry?
| KR Market | 0.38% | |
| Healthcare | 1.56% | |
| Pharma | 1.92% | |
| Pharma | 1.92% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A214370 Caregen | ₩187.50k | 37.1% +₩498.2b | 198.1% | PE71.6x | |
| A000250 Sam Chun Dang Pharm | ₩51.10k | 10.1% +₩103.7b | 42.3% | PS6.4x | |
| A039200 Oscotec | ₩20.85k | 10.8% +₩77.6b | -37.2% | PS163.6x | |
| A003520 Yungjin Pharm | ₩3.63k | 8.7% +₩53.0b | -25.9% | n/a | |
| A069620 Daewoong pharmaceuticalLtd | ₩151.50k | 2.5% +₩41.0b | 10.2% | PE20.4x |